myelodysplastic syndromes (MDS) | Page 2 | Aplastic Anemia & MDS International Foundation

myelodysplastic syndromes (MDS)

The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes

Author(s): 
Sekeres MA, Gore SD, Stablein DM, DiFronzo N, Abel GA, DeZern AE, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, Liu JJ, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, Starczynowski DT, Foran JM, Cerhan JR, Moscinski LC
Primary Author: 
Sekeres MA
Journal Title: 
Leukemia & Lymphoma
Original Publication Date: 
May 2019

Bone Marrow Diseases: 

Management of myelodysplastic syndromes after failure of response to hypomethylating agents

Author(s): 
Gil-Perez A, Montalban-Bravo G
Primary Author: 
Gil-Perez A
Journal Title: 
Therapeutic Advances in Hematology
Original Publication Date: 
May 2019

Hypomethylating agents (HMAs) are the standard of care for patients with myelodysplastic syndrome (MDS). However, only around 50% of patients respond to these agents, and responses tend to be transient, with loss of response frequently happening within 2 years and being associated with very poor prognosis and limited therapeutic options. Identification of patients who will respond to HMAs is challenging. Mechanisms underlying resistance to HMAs are not clear yet.

Bone Marrow Diseases: 

2019 Patient & Family Conference (Rockville, Maryland)

Thank you for attending the 2019 Patient & Family Conference in Rockville, Maryland. 

Event Date: 
Sat, 05/18/2019 - 7:30am
Conference Event Type: 

Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis

Author(s): 
Stahl M, Bewersdorf JP, Giri S, Wang R, Zeidan AM
Primary Author: 
Stahl M
Journal Title: 
Haemotologica
Original Publication Date: 
Apr 2019

Immunosuppressive therapy is one therapy option for treatment of patients with lower-risk

Bone Marrow Diseases: 

Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes

Author(s): 
Hsu J, Reilly A, Hayes BJ, Clough CA, Konnick EQ, Torok-Storb B, Gulsuner S, Wu D, Becker PS, Keel SB, Abkowitz JL, Doulatov S
Primary Author: 
Hsu J
Journal Title: 
Blood
Original Publication Date: 
Apr 2019

Myeloid neoplasms, including

Bone Marrow Diseases: 

MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge

Author(s): 
Sanders DS, Fennell T, Chisti MM
Primary Author: 
Sanders DS
Journal Title: 
BMJ Case Reports
Original Publication Date: 
Apr 2019

A patient with a diagnosis of myelodysplastic syndrome (MDS) with isolated 5q deletion underwent repeat

Bone Marrow Diseases: